FDA Approves First Interchangeable Biosimilar to Perjeta in HER2+ Breast Cancer | CURE

The FDA approved Poherdy as the first … “FDA approves new interchangeable biosimilar to Perjeta,” by the U.S. FDA. News release; Nov.